Company intelligence / Profile preview
VERAXA Biotech
Heidelberg, Baden-Württemberg, Germanyveraxa.com ↗
- Ownership
- Private
- Employees
- ~32
- Development stage
- Phase 1
01
Overview
VERAXA’s lead asset, VX-A901, is an Fc-enhanced therapeutic antibody targeting FLT3. It has shown potent anti-cancer activity and promising safety/tolerability in early-phase clinical trials for AML, including efficacy signals even in heavily pre-treated patients. The broader pipeline includes nine discovery/development programs across various solid and hematologic cancers
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodyT cell engager (TCE)
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
OmniAbEuropean Molecular Biology Laboratory ("EMBL")EMBLEM
Beyond the preview
Go deeper on VERAXA Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VERAXA Biotech.